Just months after Pfizer slashed hundreds of jobs in its own neuroscience R&D program, the pharmaceutical giant is making notable investments in two Boston-based neuroscience startups.
The company announced Wednesday that Tevard Biosciences and QurAlis will each receive one of Pfizer’s coveted “Golden Tickets”— a valuable voucher for the fees associated with renting a spot for one scientist for one year at LabCentral, a biotech incubator in Cambridge, Mass. For companies based elsewhere, the ticket also allows a startup to set up shop at the noted space in Kendall Square.
Perhaps more importantly, the tickets also indicate that a small company may have a big future.
About the Author Reprints
